Company’s Executive Chairman and CEO to Speak on Cancer Therapeutics Spotlight Panel at BioFuture in NYC and Deliver Keynote Address at Global Biotechnology Summit in Abu Dhabi PHILADELPHIA , Oct. 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that Dr. Raza Bokhari , Executive Chairman and Chief Executive Officer, will present at BioFuture 2026 in New York City and deliver a keynote at Global Biotechnology Summit 2026 in Abu Dhabi . The presentations will highlight the Company's progress around targeted cancer therapeutics, anchored by CD228V, an investigational antibody-drug conjugate (ADC) molecule utilizing an established vedotin linker-payload platform, as well as SkinJect®, an investigational localized immuno-oncology precision product, for multiple basal cell carcinoma lesions in patients with Gorlin syndrome, a rare autosomal dominant genetic disease. BioFuture 2026 Event dates: Oct. 27–28, 2026 Presentation date and time: Oct. 27, 2026 , from 2:00 to 2:55 p.m. ET Participation: Dr. Bokhari will participate in Spotlight Panel 3A, “Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics,” which will explore next-generation cell therapies, AI-enabled cancer drug discovery and personalized oncology approaches powered by precision medicines and advanced platforms. Location: Cure, 345 Park Avenue South , New York, NY BioFuture brings together therapeutic innovators, investors and policymakers to examine the convergence of biopharma with AI, digital medicine and data, and to assess the trends shaping the future of the industry. Global Biotechnology Summit 2026 Event dates: Nov. 11–12, 2026 Presentation date and time: Nov. 12, 2026 , at 11:45 a.m. GST Participation: Dr. Bokhari will deliver the keynote address, “Precision Medicine: From Capital to Success,” which will cover funding precision medicine breakthroughs and scaling personalized healthcare solutions from research to market. Location: ADNEC Marina , Abu Dhabi , UAE The Global Biotechnology Summit brings together scientists, investors, policymakers and industry leaders to discuss developments in biotechnology and healthcare, connect with potential partners and explore investment opportunities. Parties interested in connecting with Medicus in conjunction with either conference may contact the Company using the details below. Advancing a Focused Precision Oncology Portfolio CD228V is an early clinical-stage ADC, utilizing Pfizer’s established vedotin linker-payload platform. Medicus is prioritizing clinical proof-of-concept in melanoma, particularly relapsed, refractory or immunotherapy-resistant disease, with biomarker research intended to guide further development. The Company believes that evidence generated in melanoma could support evaluation in additional CD228-expressing solid tumors. SkinJect® complements this oncology focus as an investigational localized immuno-oncology precision product designed to deliver doxorubicin directly into basal cell carcinoma lesions through a dissolvable microneedle patch. Medicus is focusing its future internally sponsored SkinJect® clinical development exclusively on patients with Gorlin syndrome, a rare inherited condition associated with multiple and recurrent basal cell carcinomas. The FDA has authorized initiation of SKNJCT-005, the Company’s planned registrational Phase 2b study in this population. Medicus aims to build clinical evidence in defined patient populations while pursuing partnerships that can contribute expertise and development resources. CD228V and SkinJect remain investigational; their safety and efficacy for the proposed uses have not been established. For further information contact: Carolyn Bonner , President and Chief Financial Officer(610) 636-0184 cbonner@medicuspharma.com Anna Baran-Djokovic , SVP Investor Relations (305) 615-9162 adjokovic@medicuspharma.com About Medicus Pharma Ltd. Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is actively engaged in multiple countries across three continents. The Company’s current therapeutic assets are: CD228V ADC, an investigational antibody-drug conjugate molecule utilizing Pfizer’s established vedotin linker-payload platform , directed against melanotransferrin (CD228), a cell-surface protein expressed across multiple solid tumor types, such as melanoma, squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer. SkinJect ® , an investigational novel localized immuno-oncology precision product focused on basal cell carcinoma (BCC) lesions in Gorlin Syndrome patients , a rare autosomal dominant disease also called nevoid BCC syndr